Companies Anaptysbio
Anaptysbio (ANAB): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Anaptysbio’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $7,461,920FY2023
- $13,630,292FY2024
- $6,133,943FY2025
CEO total pay was $6,133,943 in fiscal 2025, down from $13,630,292 in fiscal 2024.
FY2025: salary $706,011 · bonus $0 · stock awards $1,592,001 · option awards $3,345,653
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Daniel Faga | $706,011 | $0 | $1,592,001 | $3,345,653 | $465,968 | $0 | $24,310 | $6,133,943 |
| President and Chief Executive Officer and Director | ||||||||
| Paul Lizzul | 545,754 | 0 | 505,703 | 1,064,476 | 221,031 | 0 | 28,413 | 2,365,377 |
| Chief Medical Officer | ||||||||
| Dennis Mulroy | 510,070 | 0 | 397,444 | 836,687 | 224,431 | 0 | 39,295 | 2,007,927 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Daniel Faga | $6,133,943 | $13,630,292 | $7,461,920 | ↓ −7,496,349 |
| Paul Lizzul | 2,365,377 | 4,583,508 | 2,441,117 | ↓ −2,218,131 |
| Dennis Mulroy | 2,007,927 | 3,238,907 | — | ↓ −1,230,980 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The company's compensation philosophy is performance-oriented and focused on creating long-term value, heavily weighting variable, at-risk performance-based bonuses and long-term equity awards to align executive interests with stockholder returns. As a pre-revenue biotechnology company, the program emphasizes long-term incentive compensation in the form of equity awards relative to cash compensation to reward the achievement of business and financial objectives.
| CEO STI target (% of salary) | 60% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Alpine Rewards |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Daniel Faga | Option | — | — | — | — | — | $3,345,653 |
| Dennis Mulroy | Option | — | — | — | — | — | 836,687 |
| Paul Lizzul | PSU | — | — | — | — | — | 505,703 |
| Daniel Faga | PSU | — | — | — | — | — | 1,592,001 |
| Paul Lizzul | Option | — | — | — | — | — | 1,064,476 |
| Dennis Mulroy | PSU | — | — | — | — | — | 397,444 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Daniel Faga | $0 | $1,592,001 | $3,345,653 | 32.2% |
| Dennis Mulroy | 0 | 397,444 | 836,687 | 32.2% |
| Paul Lizzul | 0 | 505,703 | 1,064,476 | 32.2% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Paul Lizzul | Option | 2,917 | 30.44 | — |
| Dennis Mulroy | Option | 2,917 | 30.44 | — |
| Dennis Mulroy | RSU | 10,490 | — | 208,331 |
| Paul Lizzul | RSU | 12,290 | — | 595,819 |
| Dennis Mulroy | Option | 15,508 | 23.23 | — |
| Paul Lizzul | Option | 18,165 | 23.23 | — |
| Dennis Mulroy | PSU | 20,000 | — | 969,600 |
| Dennis Mulroy | RSU | 24,877 | — | 439,171 |
| Dennis Mulroy | RSU | 26,800 | — | 1,299,264 |
| Paul Lizzul | RSU | 31,665 | — | 1,535,119 |
| Paul Lizzul | RSU | 34,100 | — | 1,653,168 |
| Daniel Faga | RSU | 35,700 | — | 1,730,736 |
| Dennis Mulroy | Option | 47,281 | 21.19 | — |
| Paul Lizzul | PSU | 50,000 | — | 2,424,000 |
| Daniel Faga | Option | 52,785 | 23.23 | — |
| Paul Lizzul | Option | 60,177 | 21.19 | — |
| Dennis Mulroy | Option | 76,400 | 14.83 | — |
| Paul Lizzul | Option | 97,200 | 14.83 | — |
| Daniel Faga | RSU | 104,032 | — | 5,043,471 |
| Daniel Faga | RSU | 107,350 | — | 5,204,328 |
| Daniel Faga | PSU | 160,000 | — | 7,756,800 |
| Daniel Faga | Option | 197,719 | 21.19 | — |
| Daniel Faga | Option | 305,500 | 14.83 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| John OrwinIndependent · Board Chair · Nominating/Governance | $100,000 | $89,425 | $180,808 | $0 | $0 | $370,233 |
| J. Anthony Ware, M.DIndependent · Audit · Nominating/Governance | 70,000 | 89,425 | 180,808 | 0 | 0 | 340,233 |
| John P. SchmidIndependent · Audit (Chair) · Compensation | 66,750 | 89,425 | 180,808 | 0 | 0 | 336,983 |
| Dennis Fenton, Ph.DIndependent · Compensation (Chair) | 65,000 | 89,425 | 180,808 | 0 | 0 | 335,233 |
| Magda Marquet, Ph.DIndependent · Audit | 50,000 | 89,425 | 180,808 | 0 | 0 | 320,233 |
| Hollings RentonIndependent · Nominating/Governance (Chair) | 50,000 | 89,425 | 180,808 | 0 | 0 | 320,233 |
| Rita Jain, M.DIndependent · Compensation | 46,750 | 89,425 | 180,808 | 0 | 0 | 316,983 |
| Daniel FagaEmployee director | 0 | 0 | 0 | 0 | 0 | 0 |
| Oleg NodelmanIndependent · Nominating/Governance | 0 | 0 | 0 | 0 | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $448,500 |
| Equity awards (grant-date value) | $625,975 |
| All other compensation | $0 |
| Total cost of the board | $1,074,475 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Anaptysbio as a peer
Companies that benchmark against ANAB
19 companies name ANAB as a compensation peer
The list of companies that name ANAB as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Arcellx | 2024 | Rami Elghandour | $653,288 | $9,342,069 | $10,850,151 | $0 | $21,402,668 |
| 2 | Janux Therapeutics | 2025 | David Campbell | 680,000 | 0 | 12,459,031 | 367,200 | 13,506,231 |
| 3 | Centessa Pharmaceuticals | 2025 | Saurabh Saha | 683,884 | 0 | 10,755,360 | 0 | 11,877,244 |
| 4 | Kymera Therapeutics | 2025 | Nello Mainolfi | 693,000 | 0 | 7,318,859 | 519,750 | 8,545,609 |
| 5 | Astria Therapeutics | 2024 | Jill Milne | 637,868 | 0 | 5,637,078 | 318,934 | 6,604,416 |
| 6 | Allogene Therapeutics | 2025 | David Chang | 724,000 | 2,409,537 | 2,588,329 | 400,010 | 6,136,093 |
| 7 | Anaptysbio | 2025 | Daniel Faga | 706,011 | 1,592,001 | 3,345,653 | 465,968 | 6,133,943 |
| 8 | iTeos Therapeutics | 2024 | Michel Detheux | 628,684 | 0 | 4,965,264 | 421,014 | 6,085,657 |
| 9 | Replimune Group | 2026 | Sushil Patel | 700,000 | 3,376,003 | 1,448,325 | 315,000 | 5,845,982 |
| 10 | Xencor | 2025 | Bassil Dahiyat | 742,800 | 1,552,892 | 2,727,018 | 490,248 | 5,521,205 |
| 11 | Jasper Therapeutics | 2024 | Ronald Martell | 727,272 | 438,000 | 1,740,640 | 309,091 | 3,215,003 |
| 12 | IGM Biosciences | 2023 | Fred Schwarzer | 646,797 | 868,050 | 1,336,743 | 355,738 | 3,207,328 |
| 13 | ALX Oncology | 2025 | Jason Lettmann | 724,500 | 0 | 1,447,488 | 298,856 | 2,470,844 |
| 14 | Apogee Therapeutics | 2025 | Michael Henderson | 700,000 | 0 | 0 | 591,500 | 1,291,500 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Anaptysbio | 110% | not disclosed | No | Alpine Rewards |
| Allogene Therapeutics | not disclosed | Option 55 · RSU 25 · PSU 20 | not disclosed | Compensia |
| ALX Oncology | not disclosed | not disclosed | not disclosed | Compensia |
| Apogee Therapeutics | not disclosed | Option 100 | not disclosed | Alpine Rewards |
| Arcellx | 140% | not disclosed | No | Meridian Compensation Partners |
| Astria Therapeutics | not disclosed | Option 100 | not disclosed | Aon |
| Centessa Pharmaceuticals | not disclosed | not disclosed | not disclosed | not disclosed |
| IGM Biosciences | not disclosed | not disclosed | not disclosed | Aon |
| iTeos Therapeutics | not disclosed | not disclosed | not disclosed | Radford |
| Janux Therapeutics | 90% | not disclosed | not disclosed | FW Cook |
| Jasper Therapeutics | not disclosed | not disclosed | not disclosed | not disclosed |
| Kymera Therapeutics | 125% | not disclosed | No | Alpine Rewards |
| Replimune Group | not disclosed | not disclosed | No | Pearl Meyer |
| Xencor | 110% | Options 60 · RSU 40 | not disclosed | Aon |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-08-11 | 21,274,791 | 609,979 | 33,394 | 97.21% | Passed |
| 2025 | 2025-06-17 | 17,781,545 | 6,590,193 | 1,304,913 | 72.96% | Passed |
| 2024 | 2024-06-12 | 19,874,097 | 2,954,956 | 3,397 | 87.06% | Passed |
| 2023 | 2023-06-15 | 15,221,869 | 7,185,726 | 2,237 | 67.92% | Passed |
| 2022 | 2022-06-23 | 21,241,128 | 1,166,695 | 7,245 | 94.79% | Passed |
| 2021 | 2021-06-17 | 20,696,275 | 91,221 | 4,277 | 99.56% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-08-11 | 97.21%a |
| 2025 | 2025-06-17 | 72.96%b |
| 2024 | 2024-06-12 | 87.06%c |
a. Voting standard not stated in the filing.
b. Approved under the standard stated in the filing — “Abstentions and broker non-votes will have no effect on the outcome of the vote.”.
c. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 1 : 1 |
|---|---|
| CEO total compensation | $6,133,943 |
| Median employee compensation | — |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Dividend-equivalent accruals | 2026-09-15 | — | 1,300 | — | — | 1 insider, 1 accrual row | ||
| John Orwin | Director | 2026-09-15 | A | 1,300 | 0 | 0 | Common | Form 4 ↗ |
| Hollings Renton | Director | 2026-10-01 | D | 5,000 | 50 | 249,372 | Common | Form 4 ↗ |
| Hollings Renton | Director | 2026-10-01 | A | 5,000 | 18 | 90,150 | Common | Form 4 ↗ |
| Hollings Renton | Director | 2026-10-01 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
View all 5 transactions
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| John Orwin | Director | 2026-09-15 | D | 1,300 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| John Orwin | Director | 2026-09-15 | A | 1,300 | 0 | 0 | Common | Form 4 ↗ |
| Hollings Renton | Director | 2026-10-01 | D | 5,000 | 50 | 249,372 | Common | Form 4 ↗ |
| Hollings Renton | Director | 2026-10-01 | A | 5,000 | 18 | 90,150 | Common | Form 4 ↗ |
| Hollings Renton | Director | 2026-10-01 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Sources (44 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Daniel Faga. DEF 14A, filed 2026-06-29. Section “Executive Compensation” · page 37. As printed: 6,133,943. View filing ↗
- Section 01, Paul Lizzul. DEF 14A, filed 2026-06-29. Section “Executive Compensation”. As printed: 2,365,377. View filing ↗
- Section 01, Dennis Mulroy. DEF 14A, filed 2026-06-29. Section “Executive Compensation”. As printed: 2,007,927. View filing ↗
- Section 03, Daniel Faga Option. DEF 14A, filed 2026-06-29. Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Dennis Mulroy Option. DEF 14A, filed 2026-06-29. Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Paul Lizzul PSU. DEF 14A, filed 2026-06-29. Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Daniel Faga PSU. DEF 14A, filed 2026-06-29. Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Paul Lizzul Option. DEF 14A, filed 2026-06-29. Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 03, Dennis Mulroy PSU. DEF 14A, filed 2026-06-29. Section “EXECUTIVE COMPENSATION” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-06-29. Section “CEO Pay Ratio”. As printed: 1 : 1. View filing ↗
- Section 08, John Orwin. DEF 14A, filed 2026-06-29. Section “Director Compensation”. As printed: 370,233. View filing ↗
- Section 08, J. Anthony Ware, M.D. DEF 14A, filed 2026-06-29. Section “Director Compensation”. As printed: 340,233. View filing ↗
- Section 08, John P. Schmid. DEF 14A, filed 2026-06-29. Section “Director Compensation”. As printed: 336,983. View filing ↗
- Section 08, Dennis Fenton, Ph.D. DEF 14A, filed 2026-06-29. Section “Director Compensation”. As printed: 335,233. View filing ↗
- Section 08, Magda Marquet, Ph.D. DEF 14A, filed 2026-06-29. Section “Director Compensation”. As printed: 320,233. View filing ↗
- Section 08, Hollings Renton. DEF 14A, filed 2026-06-29. Section “Director Compensation”. As printed: 320,233. View filing ↗
- Section 08, Rita Jain, M.D. DEF 14A, filed 2026-06-29. Section “Director Compensation”. As printed: 316,983. View filing ↗
- Section 08, Daniel Faga. DEF 14A, filed 2026-06-29. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Oleg Nodelman. DEF 14A, filed 2026-06-29. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, John Orwin 2026-09-15. Form 4, filed 2026-09-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Orwin 2026-09-15. Form 4, filed 2026-09-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hollings Renton 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hollings Renton 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Hollings Renton 2026-10-01. Form 4, filed 2026-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-08-11. Item 5.07 · say-on-pay result. As reported: 97.21% (votes for as printed: 21,274,791). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-17. Item 5.07 · say-on-pay result. As reported: 72.96% (votes for as printed: 17,781,545). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-12. Item 5.07 · say-on-pay result. As reported: 87.06% (votes for as printed: 19,874,097). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 448,500 + equity 625,975 + all other 0 = 1,074,475, summed across the director compensation table rows.
- Arcellx, Section 10b CEO total. DEF 14A, filed 2025-04-17. CEO total compensation as printed in Arcellx's own proxy. As printed: 21,402,668. View filing ↗
- Janux Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Janux Therapeutics's own proxy. As printed: 13,506,231. View filing ↗
- Centessa Pharmaceuticals, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Centessa Pharmaceuticals's own proxy. As printed: 11,877,244. View filing ↗
- Kymera Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Kymera Therapeutics's own proxy. As printed: 8,545,609. View filing ↗
- Astria Therapeutics, Section 10b CEO total. DEF 14A, filed 2025-04-28. CEO total compensation as printed in Astria Therapeutics's own proxy. As printed: 6,604,416. View filing ↗
- Allogene Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Allogene Therapeutics's own proxy. As printed: 6,136,093. View filing ↗
- Anaptysbio (subject), Section 10b CEO total. DEF 14A, filed 2026-06-29. CEO total compensation as printed in Anaptysbio's own proxy. As printed: 6,133,943. View filing ↗
- iTeos Therapeutics, Section 10b CEO total. DEF 14A, filed 2025-04-24. CEO total compensation as printed in iTeos Therapeutics's own proxy. As printed: 6,085,657. View filing ↗
- Replimune Group, Section 10b CEO total. DEF 14A, filed 2026-07-29. CEO total compensation as printed in Replimune Group's own proxy. As printed: 5,845,982. View filing ↗
- Xencor, Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Xencor's own proxy. As printed: 5,521,205. View filing ↗
- Jasper Therapeutics, Section 10b CEO total. DEF 14A, filed 2025-05-19. CEO total compensation as printed in Jasper Therapeutics's own proxy. As printed: 3,215,003. View filing ↗
- IGM Biosciences, Section 10b CEO total. DEF 14A, filed 2024-04-26. CEO total compensation as printed in IGM Biosciences's own proxy. As printed: 3,207,328. View filing ↗
- ALX Oncology, Section 10b CEO total. DEF 14A, filed 2026-04-20. CEO total compensation as printed in ALX Oncology's own proxy. As printed: 2,470,844. View filing ↗
- Apogee Therapeutics, Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Apogee Therapeutics's own proxy. As printed: 1,291,500. View filing ↗